Biology of Tissue Factor Pathway Inhibitor

Jeremy P. Wood,1 Paul E. R. Ellery,1 Susan A. Maroney,1 and Alan E. Mast1,2

1Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI

2Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI

Short Title: TFPI Biology

Scientific category: Thrombosis and Hemostasis

Correspondence to: Alan E. Mast

Blood Research Institute

Blood Center of Wisconsin

PO Box 2178

Milwaukee, WI 53201

alan.mast@bcw.edu

414-937-6310

414-937-6283 (FAX)
Abstract

Recent studies of the anticoagulant activities of the tissue factor (TF) pathway inhibitor (TFPI) isoforms, TFPIα and TFPIβ, have provided new insight into the biochemical and physiological mechanisms that underlie bleeding and clotting disorders. TFPIα and TFPIβ have tissue-specific expression patterns and anticoagulant activities. An alternative splicing event in the 5’ untranslated region allows for translational regulation of TFPIβ expression. TFPIα has three Kunitz-type inhibitor domains (K1, K2, K3) and a basic C-terminus, while TFPIβ has the K1 and K2 domains attached to a glycosylphosphatidyl inositol-anchored C-terminus. TFPIα is the only isoform present in platelets, while endothelial cells produce both isoforms, secreting TFPIα and expressing TFPIβ on the cell surface. TFPIα and TFPIβ inhibit both TF-factor VIIa-dependent factor Xa (FXa) generation and free FXa. Protein S enhances FXa inhibition by TFPIα. TFPIα produces isoform-specific inhibition of prothrombinase during the initiation of coagulation, an anticoagulant activity that requires an exosite interaction between its basic C-terminus and an acidic region in the factor Va B-domain. Platelet TFPIα may be optimally localized to dampen initial thrombin generation. Similarly, endothelial TFPIβ may be optimally localized to inhibit processes that occur when endothelial TF is present, such as during the inflammatory response.
Tissue factor pathway inhibitor (TFPI) is the primary inhibitor of the initiation of blood coagulation and modulates the severity of a wide variety of bleeding and clotting disorders. TFPI impedes the early stages of the blood coagulation cascade through high affinity inhibition of two coagulation proteases, tissue factor-factor VIIa (TF-FVIIa)\(^1\)\(^-\)\(^3\) and factor Xa (FXa)\(^2\)\(^,\)\(^3\). This review is focused on the two major isoforms of TFPI, TFPI\(\alpha\) and TFPI\(\beta\). These isoforms differ in their affinity for factor V/Va (FV/FVa)\(^4\)\(^,\)\(^5\) and protein S (PS)\(^6\)\(^-\)\(^9\), their tissue expression\(^10\)\(^-\)\(^13\), their mechanism for association with cell surfaces\(^14\)\(^-\)\(^17\), and their ability to impede early blood coagulation through inhibition of TF-FVIIa activity\(^3\) or inhibition of prothrombinase activity\(^5\).

Following vascular injury, TF is exposed to the blood and tightly binds the circulating serine protease FVIIa\(^18\)\(^-\)\(^20\), increasing FVIIa catalytic activity by ~30,000-fold\(^21\)\(^,\)\(^22\). The TF-FVIIa complex initiates the blood coagulation cascade by activating factor X (FX) and factor IX (FIX)\(^21\)\(^,\)\(^22\). Additionally, factor IXa (FIXa) forms a complex with its cofactor protein, factor VIIIa (FVIIIa), which also activates FX\(^23\). FXa binds its cofactor protein, FVa, to form prothrombinase, an enzymatic complex which rapidly converts prothrombin to thrombin\(^24\)\(^,\)\(^25\). Thrombin then performs a number of procoagulant functions, including the activation of platelets\(^26\), FV\(^27\)\(^,\)\(^28\), factor VIII (FVIII)\(^29\)\(^,\)\(^30\), and factor XI\(^31\)\(^,\)\(^32\), as well as cleavage of fibrinogen to fibrin\(^33\).

Deficiency of either FVIII or FIX manifests as the bleeding disorder hemophilia A or hemophilia B, respectively. Although the TF-FVIIa complex is known to activate FX directly, when small amounts of TF were added to FVIII- or FIX-deficient plasma, very little FXa was generated\(^34\). This early experimental finding is consistent with the bleeding phenotypes observed in patients with hemophilia and suggested the presence of a plasma protein that inhibited TF-
FVIIa from activating FX. Further studies showed that this inhibitory activity was reversible and required the presence of FVIIa, FXa, and calcium ions. These early studies led to the isolation and cloning of a coagulation inhibitor of TF-FVIIa-mediated activation of FX. This inhibitor was originally referred to as either lipoprotein-associated coagulation inhibitor (LACI) or extrinsic pathway inhibitor (EPI), and eventually came to be known as tissue factor pathway inhibitor (TFPI). Two major isoforms of TFPI, resulting from an alternative splicing event, have now been described in both mice and humans: (1) TFPIα, which contains three Kunitz-type inhibitory domains (K1, K2, K3) and a positively-charged C-terminus; and (2) TFPIβ, which contains the K1 and K2 domains of TFPIα, followed by a unique C-terminus encoding for addition of a glycosylphosphatidylinositol (GPI) anchor. The K1 and K2 domains bind and inhibit FVIIa and FXa, respectively, while the K3 domain has no known inhibitory function.

Clinical Studies of TFPI

TFPI and Thrombosis

Early studies using rabbit models demonstrated that immunodepletion of TFPI increases susceptibility to development of disseminated intravascular coagulation (DIC) following infusion of TF, evidence that TFPI is the primary regulator of TF-induced coagulation in vivo. Similarly, TFPI depletion increases susceptibility to endotoxin-induced DIC and the generalized Schwartzman reaction, characterized by fibrin deposition and hemorrhagic necrosis in the kidneys. Subsequently, genetically altered mice lacking the K1 domain of TFPI (TFPI<sup>tm1Gjb</sup>; tfpi<sup>−/−</sup>) were produced and found to succumb to embryonic lethality from an apparent consumptive coagulopathy. Mice with heterozygous deficiency (tfpi<sup>+/−</sup>) demonstrate growth and
development, reproductive capability, and survival comparable to tfpi+/+ mice\textsuperscript{51}. The tfpi+/− mice do not exhibit a generalized prothrombotic state under normal husbandry conditions, as evidenced by plasma thrombin-antithrombin complex levels comparable to tfpi+/+ mice\textsuperscript{52}. Furthermore, there is no difference between tfpi+/+ and tfpi+/− mice in time to occlusion following photochemical injury of the carotid artery\textsuperscript{53}, fibrin formation parameters measured by thromboelastography\textsuperscript{54}, or tail bleeding time\textsuperscript{54}. However, tfpi+/− mice have increased thrombus volume following femoral vein electrolytic injury, suggesting the presence of a mild procoagulant state\textsuperscript{52}. This mild procoagulant state is noticeably enhanced by breeding TFPI heterozygosity with other procoagulant mutations such as FV Leiden (F5\textsuperscript{tm2Dgi})\textsuperscript{55}, apolipoprotein E deficiency (Apoe\textsuperscript{tm1Unc/J})\textsuperscript{53}, and partial thrombomodulin deficiency (Thbd\textsuperscript{tm1Wlr})\textsuperscript{52}. Additionally, mice lacking only hematopoietic cell TFPI, which is primarily in platelets, also have increased clot volume following vascular injury\textsuperscript{56}, while mice lacking endothelial TFPI have decreased time to vascular occlusion following ferric chloride injury\textsuperscript{57}.

Total TFPI deficiency has not been described clinically, suggesting that it also produces embryonic lethality in humans. Similar to what has been described in the murine system, partial TFPI deficiency also appears to be a rather weak prothrombotic risk factor in humans. Patients with plasma TFPI\textalpha (also called “full-length” or “free” TFPI) at or below the 10\textsuperscript{th} percentile of the normal reference range were found to have slightly increased risk for venous thrombosis\textsuperscript{58} and an increased risk for coronary heart disease\textsuperscript{59}. Numerous other studies have correlated low plasma TFPI concentration with prothrombotic clinical disease, including atherosclerosis, coronary artery disease, ischemic stroke, and peripheral artery occlusive disease. These have been recently reviewed by Winckers and colleagues\textsuperscript{60}. Also of clinical interest is that oral estrogen therapy produces an approximately 25\% reduction in total plasma TFPI concentration
and activity. It remains unclear how this may contribute to the procoagulant state associated with estrogen therapies. However, estrogen use appears to synergize with other risk factors. For example, women with FV Leiden who use oral contraceptives have greatly elevated thrombotic risk compared to women with only one of these risk factors. The severe perinatal thrombosis observed in mice with combined FV Leiden and heterozygous TFPI deficiency, described above, suggests a potential mechanism by which oral contraceptives decrease plasma TFPI concentration, reducing anticoagulant activity and this, coupled with the procoagulant FV Leiden phenotype, results in the elevated thrombotic risk.

The underlying reasons for the weak correlation between TFPI deficiency and thrombosis in humans are not entirely understood, but may lie in the assays available for clinical measurement of TFPI in plasma, which are complicated by several factors. Plasma TFPI can be measured either as TFPIα, which is not bound to lipoproteins, or as total TFPI, which is partially C-terminally truncated and associates tightly with lipoproteins. TFPIα, which contributes ~10–30% of the total plasma TFPI pool, is thought to be the more active anticoagulant. The plasma concentration of TFPIα promptly increases 2- to 4-fold following heparin infusion, suggesting that a large portion of TFPIα within the vasculature is associated with the endothelium and, therefore, is not measured in peripheral blood assays. This point is emphasized by patients with abetalipoproteinemia, who have very low amounts of plasma TFPI but normal amounts of heparin-releasable TFPI and do not have increased risk for thrombosis. In addition, as discussed in more detail below, studies using cultured endothelial cells have identified an intracellular pool of TFPIα that is released following heparin treatment. Thus, measurement of plasma TFPI is likely not a reliable indicator of the intravascular TFPI anticoagulant activity present in an individual patient. TFPIα is also present within platelets. Development of
assays that accurately measure platelet TFPI may provide a more reliable clinical indicator of intravascular TFPI activity and a patient’s risk for thrombotic disease.

**TFPI and Bleeding**

The association of TFPI with bleeding disorders, such as hemophilia and a recently characterized mutation within the FV gene (east Texas bleeding disorder)\(^{67,68}\), has led to a greater understanding of the interdependent relationship between the procoagulant and anti-coagulant mechanisms of hemostasis. The importance of TFPI as a modulator of bleeding in hemophilia could be hypothesized because, in its absence, the TF-FVIIa complex would generate increased FXa, even in the absence of FVIII or FIX, thus allowing for more significant thrombin production and clot formation. This hypothesis is supported by early studies, which showed that TFPI is an important regulator of coagulation in hemophilia A or B plasma\(^{69,70}\) and in a reconstituted system, containing physiologic concentrations of purified coagulation factors but lacking either FVIII or FIX\(^{71}\). These *in vitro* studies suggest that the severe bleeding in patients with hemophilia requires not only the absence of FVIII or FIX, but also the presence of TFPI. This activity of TFPI is mediated by blocking direct activation of FX by TF-FVIIa, thereby requiring hemostatic thrombin generation to occur through activation of FIX and its cofactor, FVIII\(^{34}\). Therefore, inhibition of TFPI activity has been investigated as a treatment strategy for hemophilia and has been demonstrated to improve hemostasis in several hemophilia animal models\(^{54,72-76}\). One of these agents, BAX499\(^{77,78}\), an aptamer which inhibits TFPI\(^{72}\) by binding multiple sites, including K1, K3, and the C-terminus\(^{79}\), initially showed promise as a novel therapeutic for treatment of hemophilia\(^{80,81}\). However, in humans, it induced release of TFPI\(^{72}\) from endothelial cells, stabilized the protein, and prevented its uptake and degradation, resulting
in a substantial increase in TFPIα concentration (>25-fold under some conditions)\textsuperscript{77}. The aptamer was not able to counteract the anticoagulant effect of this greatly elevated TFPI, bleeding resulted, and further development was stopped\textsuperscript{78}. Other pharmaceutical agents that block TFPI activity continue to be developed for treatment of hemophilia\textsuperscript{76,82}. Recent work from our laboratory demonstrated that deficiency of hematopoietic cell TFPI improved hemostasis in mice with FVIII deficiency\textsuperscript{54}. These data suggest that inhibition of FXa and prothrombinase on the platelet surface by TFPIα (discussed below) may also contribute to bleeding severity in hemophilia and that pharmaceutical agents targeting only platelet TFPI released at a site of vascular injury may be sufficient to mitigate bleeding in patients with hemophilia.

TFPIα is also thought to modulate bleeding in FV-deficient patients\textsuperscript{83,84}. The C-terminus of TFPIα interacts with FV\textsuperscript{4}. Patients with plasma FV deficiency are also deficient in plasma TFPIα, suggesting that these two proteins interact in plasma\textsuperscript{84}. This reduced TFPIα concentration allows for a small amount of thrombin generation in platelet-rich plasma from FV-deficient individuals, attributable to the low concentration of platelet FVa present in these patients\textsuperscript{83}. Therefore, it has been suggested that reduced TFPIα protects FV-deficient individuals from bleeding\textsuperscript{83,84}.

The interaction between TFPIα and FV also contributes to the east Texas bleeding disorder, which is caused by a FV mutation (FVA2440G) that results in an alternative splicing event and removal of most of the FV B-domain\textsuperscript{67,68}. This “FV-short” isoform retains the acidic region of its B-domain\textsuperscript{68}, which tightly binds the TFPIα basic region\textsuperscript{5}. This interaction results in an ~10-20-fold increase in circulating TFPIα, the reason for which is unknown but thought to reflect a stabilization of TFPIα by FV-short\textsuperscript{68}, and produces a moderately severe bleeding phenotype, characterized by bruising, epistaxis, and excessive blood loss following minor
trauma, sometimes requiring blood transfusion for treatment\textsuperscript{67,68}. Very low concentrations of
FV-short were also detected in the plasma of individuals without east Texas bleeding disorder, and TFPI\textsubscript{α} was shown to preferentially bind to FV-short compared to full-length FV\textsuperscript{68}. Therefore, FV-short may be the primary form of plasma FV that interacts with TFPI\textsubscript{α} under normal physiologic conditions, although this has not been directly demonstrated.

**Alternative Splicing Produces TFPI Isoforms with Distinct Structures**

TFPI is an alternatively spliced protein with multiple, independent, splicing events occurring at both the 3’ and 5’ ends of the TFPI pre-mRNA (Figure 1). Alternative splicing at the 3’ end produces several TFPI protein isoforms with distinct anticoagulant activities. The major isoforms, TFPI\textsubscript{α} and TFPI\textsubscript{β}, are produced in all mammals. Other “minor” isoforms, identified only at the transcript level, include TFPI\textsubscript{γ}\textsuperscript{85}, produced only in mice, and TFPI\textsubscript{δ}\textsuperscript{86,87}, produced only in humans. The structure of these has been reviewed in detail elsewhere\textsuperscript{86,87}. The TFPI\textsubscript{α} and TFPI\textsubscript{β} isoforms are differentially expressed in platelets and endothelial cells, respectively, and have different mechanisms for association with cell surfaces. TFPI\textsubscript{α} interacts with coagulation proteins FV/FVa and PS, ultimately producing unique mechanisms through which this isoform inhibits blood clotting. TFPI\textsubscript{β} contains a GPI anchor attachment sequence and is directly bound to endothelium\textsuperscript{17,48}. The mRNA splicing pattern of TFPI\textsubscript{α} and TFPI\textsubscript{β} is depicted in Figure 1.

Exons 3 through 7 encode the N-terminus, first and second Kunitz-type inhibitory domains (K1 and K2, respectively), and linker regions common to TFPI\textsubscript{α} and TFPI\textsubscript{β}. Splicing to exons 9 and 10 produces TFPI\textsubscript{α}, which contains a third Kunitz domain (K3) that binds PS\textsuperscript{8} and a highly basic C-terminus that binds FV/FVa\textsuperscript{4,5}. Splicing to exon 8 produces TFPI\textsubscript{β} with its GPI-anchor\textsuperscript{17,48}. 
Alternative splicing within the 5’ UTR occurs in approximately 12% of human mRNA species, including TFPI, and typically allows for inclusion or removal of translational regulatory elements\textsuperscript{88}. The 5’ UTR of TFPI is encoded by two exons (exons 1 and 2) that are present in TFPI\textalpha{} and TFPI\textbeta{} message. Exon 2 is removed by alternative splicing in some transcripts\textsuperscript{89,90}. Recent data from our laboratory demonstrated that exon 2 acts as a translational repressor of TFPI\textbeta{}, but not TFPI\textalpha{}, expression. Further experiments revealed that exon 2 is a general translational repressor whose repressive effects are overcome by elements within the TFPI\textalpha{} 3’ UTR. Thus, exon 2 splicing represents a “molecular switch” that regulates TFPI\textbeta{} expression, providing a unique mechanism for regulation of TFPI isoform production, in which a 5’ alternative splicing event alters translation of a splice variant produced by a second splicing event at the 3’ end of the same pre-mRNA\textsuperscript{90}. The physiological importance of this 5’ splicing event remains to be determined but might include temporal and tissue-specific regulation of TFPI\textbeta{}-mediated anticoagulant activity.

**Differential Expression of TFPI\textalpha{} and TFPI\textbeta{} in Platelets and Endothelial Cells**

Endothelial cells and megakaryocytes are the primary cells producing TFPI\textsuperscript{10-13}. TFPI is also produced by monocytes and smooth muscle cells\textsuperscript{91-96}. Understanding the differential expression of TFPI\textalpha{} and TFPI\textbeta{} within these different sites began by investigating their mRNA expression. *In situ* hybridization demonstrated that TFPI\textalpha{} and TFPI\textbeta{} have the same cellular expression pattern, with the message for both primarily present in the vascular endothelium of tissues throughout the body\textsuperscript{85}. TFPI\textalpha{} mRNA is 5-10 times more abundant than TFPI\textbeta{} mRNA in human and mouse tissues\textsuperscript{85} as well as cultured endothelial cells\textsuperscript{97}. Despite having less abundant mRNA, TFPI\textbeta{} is the predominant TFPI isoform expressed on endothelium in murine tissues\textsuperscript{11}. 

10
TFPIβ is also the predominant isoform on cultured human endothelial cells and human placental microsomes, suggesting that TFPIβ is the predominant isoform on human endothelium, though cultured human endothelial cells also secrete TFPIα\textsuperscript{98}. It has been estimated that cultured human endothelial cells produce 10-50 times as much TFPIα as TFPIβ over a 24-hour period\textsuperscript{98}. Heparin infusion produces a prompt 2-4 fold increase in human plasma TFPIα\textsuperscript{15,16,99,100} that is not observed in mice\textsuperscript{11}. This increase is observed within 5-10 minutes of heparin infusion, and is rapidly reversed following neutralization of heparin with protamine\textsuperscript{99,100}. C-terminally truncated forms of TFPIα produced in patients undergoing cardiac bypass surgery remain in the circulation after protamine infusion\textsuperscript{99}. Collectively, these data suggested that human endothelium has a heparin-releasable pool of TFPIα bound to cell surface glycosaminoglycans through its basic C-terminal region. However, this in vivo pool of endothelial-associated TFPIα has been difficult to characterize using in vitro studies of cultured endothelial cells, which do not have a heparin-releasable form of TFPI on their surface\textsuperscript{14,101,102}. Instead, they have an intracellular store of TFPIα that is secreted as a soluble protein in a manner that can be enhanced by heparin, thrombin, or high shear force\textsuperscript{66,103,104}. Further investigation of human tissue vascular beds is needed to better define cell surface TFPI isoform expression, as well as the presence and potential physiological function of the intracellular stores of TFPIα identified in cultured endothelial cells.

Human and mouse platelets make only TFPIα\textsuperscript{12,56}. TFPIα is stored within quiescent platelets and released following platelet activation\textsuperscript{12,13}. Interestingly, platelet TFPIα is secreted as a soluble protein following platelet activation with thrombin as a single agonist\textsuperscript{13}, with a portion becoming membrane-bound at the platelet surface following platelet activation with dual agonists, such as collagen plus thrombin\textsuperscript{12}. TFPIα does not co-localize with platelet α-granule or
lysosomal proteins\textsuperscript{12}. Additional studies of its location within the platelet and the mechanism for its release are needed.

**TFPI\textalpha and TFPI\textbeta Inhibit Blood Coagulation Through Distinct Mechanisms**

TFPI\textalpha and TFPI\textbeta have distinct structural domains, mechanisms for association with cellular surfaces, and cellular expression patterns, suggesting they may yield anticoagulant activity through different biochemical mechanisms, at least some of which have been uncovered. TFPI\textalpha and TFPI\textbeta contain the same K1 and K2 domains, which bind the active sites of FVIIa and FXa, respectively\textsuperscript{2}. Therefore, both isoforms are capable of directly inhibiting FXa\textsuperscript{2} and are FXa-dependent inhibitors of TF-FVIIa\textsuperscript{1,2}, as described when TFPI was initially identified and characterized\textsuperscript{2} (Figure 2). Very recently, our laboratory characterized a previously unrecognized TFPI anticoagulant activity, the inhibition of early forms of prothrombinase\textsuperscript{5}. This inhibitory activity is produced by TFPI\textalpha but not TFPI\textbeta, and requires a high affinity exosite interaction between the C-terminal basic region of TFPI\textalpha and an acidic region in the B-domain of either FXa-activated FVa or forms of FVa released from platelet \textalpha-granules (Figures 2 and 3). Details of current knowledge of how TFPI\textalpha and TFPI\textbeta produce anticoagulant activity, through TF-dependent and –independent mechanisms, are provided in the following paragraphs.

*Inhibition of FXa by TFPI\textalpha and TFPI\textbeta*

TFPI\textalpha\textsuperscript{2} and TFPI\textbeta\textsuperscript{3} directly inhibit FXa in assays which use small molecule amidolytic substrates to measure FXa activity. The binding of PS to K3 in TFPI\textalpha and the GPI-anchor that directly localizes TFPI\textbeta to the cell surface are important differences between these two isoforms that alter their FXa inhibitory activity. TFPI\textalpha is a biphasic (slow, tight-binding) inhibitor of FXa.
and requires all Kunitz domains and the basic C-terminus for optimal activity\textsuperscript{2,8,64,105-110}. PS enhances the inhibition of FXa ~9-fold when studied using \textit{in vitro} assays measuring FXa amidolytic activity\textsuperscript{6,7}. Evidence for the physiological importance of the PS-TFPI\textsubscript{α} anticoagulant system has accumulated through a series of clinical studies demonstrating that the plasma TFPI\textsubscript{α} concentration and anticoagulant activity are decreased in PS-deficient plasma, suggesting that PS and TFPI\textsubscript{α} circulate as a complex in plasma\textsuperscript{111-113}. Functional studies of the TFPI\textsubscript{α}-PS interaction have revealed that it requires K3 residues Arg199\textsuperscript{8} and Glu226\textsuperscript{114} and the presence of a membrane surface\textsuperscript{6}. Thus, it appears that PS enhances FXa inhibition primarily by localizing TFPI\textsubscript{α} to the membrane surface, a notion supported by experiments demonstrating that PS has cofactor activity towards the soluble TFPI variant protein K1K2K3\textsuperscript{8,115} but has no cofactor activity towards the same variant protein when it is attached to the cell surface with a GPI anchor\textsuperscript{115}. In addition, PS does not enhance inhibition of FXa by cell surface-associated TFPI on primary endothelial cells or endothelial cell lines\textsuperscript{115}.

Since optimal inhibition of FXa by TFPI\textsubscript{α} requires both the K3 domain and the basic C-terminus\textsuperscript{8,64,107-110}, regions which are not present in TFPI\textsubscript{β}, one might hypothesize that TFPI\textsubscript{β} would be a relatively poor inhibitor of FXa. However, this is not the case. Membrane-associated TFPI\textsubscript{β} is a slightly better inhibitor of FXa than is soluble TFPI\textsubscript{α}\textsuperscript{3}, suggesting that the GPI-anchor circumvents the need for K3 and the C-terminus in regards to inhibition of FXa by K2. As TFPI\textsubscript{β} lacks K3, PS has no effect on its inhibitory activity\textsuperscript{115}. If the biological roles of K3, the C-terminus, and PS during the inhibition of FXa are to bind TFPI\textsubscript{α} to the membrane surface, then it is logical that tethering TFPI\textsubscript{β} to the surface through its GPI anchor would render K3, the C-terminus, and PS unnecessary.
**Inhibition of TF-FVIIa by TFPIα and TFPIβ**

TFPIα\(^1,2\) and TFPIβ\(^3,97,116,117\) are FXa-dependent inhibitors of the TF-FVIIa complex, a process which is mediated by the interactions of K1 with the active site of FVIIa and K2 with the active site of FXa\(^2\). The mechanism for inhibition of TF-FVIIa is often described as a two-step process, with initial inhibition of FXa by K2 followed by inhibition of TF-FVIIa by K1\(^118\); however, TFPI most likely binds to the TF-FVIIa-FXa ternary complex, simultaneously inhibiting FXa and TF-FVIIa immediately after FX activation, with the binding of K2 to the FXa active site as the rate-limiting step\(^1\). In contrast to its function as a cofactor for FXa inhibition (described above), the function of PS in the inhibition of TF-FVIIa by TFPIα has been less clear. PS was initially thought to promote the FXa-mediated inhibition of TF-FVIIa by TFPIα\(^6\). However, further studies revealed that PS does not alter the rate of FXa or FIXa generation by TF-FVIIa\(^7\). PS does promote the direct inhibition of FVIIa by K1, as measured using a small molecule FVIIa substrate\(^9\). This PS activity is dependent on TF, the TFPIα K3 domain, and phospholipid, suggesting PS acts by localizing TFPIα to the membrane surface, in a manner similar to how it promotes FXa inhibition. Direct inhibition of TF-FVIIa by TFPIα may be physiologically relevant in contexts where TFPIα concentration is elevated, such as at the site of clot formation, where platelet TFPIα is released\(^12,13\), or under pathologic conditions when plasma TFPIα is elevated.

TFPIβ also inhibits FXa generation by TF-FVIIa\(^3,97,116,117\), as this activity only requires the K1 and K2 domains. In fact, TFPIβ inhibits the activity of TF-FVIIa as well as or better than TFPIα\(^3\). TFPIβ is a more potent inhibitor of TF-FVIIa-mediated cellular migration *in vitro* and effectively dampens TF-mediated cellular infiltration into lung tissue in an *in vivo* mouse model, studies which utilized Chinese hamster ovary cells expressing either TF or both TF and TFPIβ\(^3\).
Similarly, suppression of TFPIβ expression in breast cancer cells results in enhanced cellular migration\(^{116}\). One explanation for the enhanced inhibitory activity of TFPIβ compared to TFPIα would be that its expression on the same cell surface as TF resulted in a dramatically enhanced local concentration, which would suggest that TFPIβ is optimized to inhibit TF that is expressed on the same cell, as may occur under inflammatory conditions. As a GPI-anchored protein, TFPIβ might be expected to localize within cell membrane microenvironments known as caveolae, as has been shown with other GPI-anchored proteins\(^{119}\). Consistent with this, cell surface TFPI on cultured cells localizes to caveolae, which enhance its anticoagulant activity\(^{14,120-122}\). Studies of TFPIβ and altered membrane-bound forms of TFPI demonstrated that localization to caveolae does not alter direct inhibition of FXa by TFPIβ, but does enhance its anti-TF activity\(^{121}\). In addition, disruption of these membrane microdomains with methyl-β-cyclodextran results in decreased inhibitory activity\(^{121}\).

The TF-FVIIa-FXa ternary complex, apart from its role in coagulation, initiates signaling pathways through proteolytic activation of the protease activated receptors 1 and 2 (PAR1 and PAR2)\(^{123}\). Studies of the ability of TFPI to inhibit the signaling activity of the ternary complex have yielded mixed results\(^{124}\). When TF activity is induced on HUVEC cells by stimulation with TNF-α, the endogenously expressed HUVEC TFPI appears to be readily capable of inhibiting ternary complex-mediated signaling events, including PAR1-mediated induction of the orphan receptor gene TR3 and PAR2-mediated phosphorylation of ERK1/2\(^{124}\). As HUVECs express primarily TFPIβ on their surface\(^{98}\), this inhibition was likely mediated by TFPIβ. In another set of experiments, HUVECs were transduced to over-express TF and overwhelm the endogenous TFPI, and exogenous TFPIα was added\(^{124}\). Under these conditions, minimal inhibition of PAR1-mediated signaling was observed, and inhibition of PAR2-mediated signaling also appeared to be
weaker. These data suggest that TFPIβ is a more potent inhibitor of TF-FVIIa-FXa-mediated signaling than is TFPIα, similar to what has been reported for TF-FVIIa-mediated FX activation and cellular migration⁵.

Inhibition of Prothrombinase by TFPIα

The inhibition of prothrombinase is a newly recognized, TF-independent and isoform-specific anticoagulant activity of TFPIα⁵. The ability of TFPIα to inhibit prothrombinase is dependent upon binding of its basic C-terminal region to an acidic region of the FV B-domain that is retained in some forms of FVa that assemble into prothrombinase. Thus, TFPIα is a potent inhibitor of prothrombinase assembled with either FXa-activated FVa or platelet-released FVa, which retain the acidic region of the FV B-domain⁵, but not with thrombin-activated FVa, which has the entire B-domain removed¹²⁵,¹²⁶ (Figure 3). This acidic region of the B-domain interacts with a basic region, also within the B-domain, to maintain FV in an inactive, procofactor conformation¹²⁷-¹²⁹. These regions appear to function by preventing FXa from binding to the FV heavy chain, and removal of either the acidic or basic region is sufficient to relieve this inhibition and convert FV into FVa¹²⁷,¹²⁸. Interestingly, the FV B-domain basic region contains an amino acid sequence almost identical to one found within the C-terminus of TFPIα. This sequence is highly conserved in both proteins across mammalian species suggesting it performs an important physiological function (Figure 4). The TFPIα basic region binds to the acidic region within FXa-activated FVa and platelet-released FVa with high affinity (Kₐ~90 pM) and, combined with the interaction between K2 and the FXa active site, allows TFPIα to inhibit prothrombinase containing either of these forms of FVa⁵ (Figure 5). This inhibitory activity is not shared by TFPIβ⁵ and is not enhanced by PS¹¹⁵.
The TFPIα-mediated inhibition of prothrombinase is anticipated to be physiologically relevant and lead to a better understanding of and treatment for bleeding and clotting disorders. Forms of FVa that retain the acidic region of the B-domain have been shown to have biological activity in two important recent studies. The first, performed by Schuijt and colleagues, used a tick anticoagulant protein (TIX-5) that specifically inhibits FXa from activating FV to demonstrate that FXa-catalyzed activation of FV is a critical event during the initiation of blood coagulation. The second, performed by Vincent and colleagues, characterized the east Texas bleeding disorder (mentioned above), finding that the moderately severe bleeding in these patients is caused by tight binding of TFPIα to the acidic region of the B-domain in the short form of FV produced in this disorder. Furthermore, TFPIα-mediated inhibition of prothrombinase is charge-dependent and thus is blocked by large, negatively-charged molecules. This is consistent with previous studies, which have shown that heparin, polyphosphate, and fucoidan have procoagulant properties in assays that rely on in situ generation of FVa (presumably through cleavage by FXa), and that heparin and polyphosphate lose these properties in the presence of thrombin-activated FVa. Thus, the inhibition of early forms of prothrombinase by TFPIα provides one explanation for the role of TFPIα in the procoagulant effects of heparin observed in the absence of antithrombin, the polyphosphate-mediated procoagulant activity of histone-stimulated PRP, and the efficacy of fucoidan administration in a dog model of hemophilia. It has also been proposed that the procoagulant effect of polyphosphate and heparin is due to acceleration of FV activation by either FXa or thrombin. This accelerated FVa generation allows for a more rapid assembly of prothrombinase, enabling FXa to escape inhibition by TFPI. It is likely that these compounds have multiple mechanisms of action.
Conclusions

TFPI was identified and cloned in the 1980's\textsuperscript{42-46}, with its mechanisms of FXa inhibition and FXa-dependent TF-FVIIa inhibition fully characterized through the 1990's\textsuperscript{1,2,41,118}. Subsequently, significant contributions have been made to the understanding of TFPI biology. We now know that there are two major TFPI isoforms produced in humans. TFPI\textalpha and TFPI\textbeta arise from an alternative splicing event, are differentially regulated at the translational level, are expressed in different cell types, and are optimized for different anticoagulant functions. The GPI-anchoring of TFPI\textbeta allows it to optimally inhibit TF-FVIIa and FXa on endothelium. TFPI\textalpha requires the aid of its cofactor PS to bind to cell surfaces and optimally inhibit FXa, though PS is not required for FXa-dependent TF-FVIIa inhibition. The C-terminus of TFPI\textalpha allows it to inhibit early forms of prothrombinase, and its localization within platelets puts it in position to inhibit prothrombinase at the initial stages of clot formation. TFPI inhibitors are currently in development to treat bleeding disorders, including hemophilia, and our improved understanding of TFPI biology will enable us to better predict the physiologic effects of these inhibitors.
Acknowledgments

This work was supported by NHLBI grants HL068835 to A. E. Mast and HL096419 and HL117702 to S. A. Maroney.

Authorship

Contribution: J.P.W., P.E.R.E., S.A.M., and A.E.M. wrote the manuscript.

Conflict-of-interest disclosure

A.E.M. receives grant support from Novo Nordisk.

The abbreviations used are: TFPI, tissue factor pathway inhibitor; TF, tissue factor; FVIIa, factor VIIa; FXa, factor Xa; PS, protein S; FV, factor V; FVa, factor Va; FX, factor X; FIX, factor IX; FIXa, factor IXa; FVIIIa, factor VIIIa; FVIII, factor VIII; LACI, lipoprotein-associated coagulation inhibitor; EPI, extrinsic pathway inhibitor; GPI, glycosylphosphatidylinositol; DIC, disseminated intravascular coagulation
References


94. Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. *Thromb Haemost.* 1995;73(5):873-875.


Figure Legends

Figure 1. Intron-exon organization of TFPI and the mRNA structure of TFPIα and TFPIβ.
The uppermost schematic diagram depicts the intron-exon organization of TFPI. TFPIα and TFPIβ mRNA species are represented below. Each box represents an exon, while the joining lines represent introns. The exons are numbered below the diagram. Dashed lines represent alternative splicing events. The region of TFPI encoded by each exon is indicated within the box. Exons encoding regions specific to TFPIα are colored orange, while that specific to TFPIβ is colored green. Key: 5’ UTR – 5’ untranslated region; N-term – N-terminus; K – Kunitz domain; L – linker region; C-term – C-terminus; β – region specific to TFPIβ.

Figure 2. TFPI Isoform Structures. Shown are the amino acid structures of TFPIα and TFPIβ. Each small circle represents an individual amino acid. Small red circles indicate the residues in K1 and K2 which bind the active sites of FVIIa and FXa, respectively; small purple circles indicate residues in K3 which bind protein S; small blue and orange circles indicate the conserved basic and hydrophobic residues, respectively, which bind the acidic region of FVa. The domains required for inhibition of TF/FVIIa, FXa, and prothrombinase (FXa/FVa) are indicated by shaded red, blue, and yellow ovals, respectively. TFPIβ is anchored to the membrane through a GPI anchor (green hexagons).

Figure 3. Biological forms of FV and FVa with different B-domain fragments. Shown are the domain structures of FV, thrombin-activated FVa (FVaⅡa), FXa-activated FVa (FVaXa), and platelet FV/FVa, which is a mixture of multiple FVa species containing B-domains of varying lengths, as well as full-length FV. The species shown are intended to indicate the heterogeneity and do not represent all of the platelet FVa species present or their relative abundance. The
heavy chain (HC; green), light chain (LC; purple), and B-domain (B; orange) are indicated. The heavy and light chains of FVa are linked through a calcium bridge (yellow diamonds). The basic and acidic regions of the B-domain are indicated in blue and red, respectively. A form of FVa that contains the B-domain basic region but lacks the acidic region has not been identified.

**Figure 4. Sequence alignment of the FV and TFPIα basic regions.** Shown are residues 995-1010 of human FV and 249-264 of human TFPIα, along with the corresponding sequences from other mammalian species. The homologous basic region is shaded grey. The conserved basic residues are blue, while the conserved hydrophobic residues are orange. Mouse TFPIα contains the indicated 6-residue insertion in the basic region. Sequences were obtained from the NCBI, UniProt, and OMA databases.

**Figure 5. Mechanism of inhibition of prothrombinase by TFPIα.** TFPIα inhibits thrombin generation by prothrombinase during the initiation phase of coagulation (upper panel) but not during the propagation phase (lower panel). This inhibition is mediated by the interaction of K2 with the active site of FXa (yellow), as well as the interaction of the TFPIα basic C-terminus (blue) with the B-domain acidic region (red), present in FXa-activated FVa and some forms of platelet-released FVa (green). This region is absent in thrombin-activated FVa. Based on the model of Bos and Camire, it may be hypothesized that the TFPIα basic region and FVa B-domain acidic region bind to the FVa heavy chain A2 domain (expanded box). This figure is modified from Wood et al.
Figure 1
Figure 3
### Factor V

<table>
<thead>
<tr>
<th>Species</th>
<th>TFPIα</th>
<th>TFPIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Chimpanzee</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Gibbon</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Rhesus Monkey</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Marmoset</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Tarsier</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Gorilla</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
</tbody>
</table>

### African Elephant

<table>
<thead>
<tr>
<th>Species</th>
<th>TFPIα</th>
<th>TFPIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>African Elephant</td>
<td>SKFLIKTKRRKRRK</td>
<td>SKFLIKTKRRKRRK</td>
</tr>
<tr>
<td>Giant Panda</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Cow</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>yak</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Horse</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Pig</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Dog</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
</tbody>
</table>

### Rodents

<table>
<thead>
<tr>
<th>Species</th>
<th>TFPIα</th>
<th>TFPIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Rat</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Hamster</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Mole Rat</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Guinea Pig</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Squirrel</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Kangaroo Rat</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
</tbody>
</table>

### Bats

<table>
<thead>
<tr>
<th>Species</th>
<th>TFPIα</th>
<th>TFPIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown Bat</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>David's Myotis</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Flying Fox</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
</tbody>
</table>

### Mars

<table>
<thead>
<tr>
<th>Species</th>
<th>TFPIα</th>
<th>TFPIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opossum</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>wallaby</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Tasmanian Devil</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
</tbody>
</table>

### Miscellaneous

<table>
<thead>
<tr>
<th>Species</th>
<th>TFPIα</th>
<th>TFPIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>platypus</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Shrew</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Rabbit</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Pika</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Ferret</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Hyrax</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Hedgehog</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Dolphin</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Armadillo</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Two-Toed Sloth</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
</tbody>
</table>

---

**Figure 4**

<table>
<thead>
<tr>
<th>Species</th>
<th>TFPIα</th>
<th>TFPIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Chimpanzee</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Orangutan</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Rhesus Monkey</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Bushbaby</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Tarsier</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
<tr>
<td>Gorilla</td>
<td>KGGLIKTKRRKRRK</td>
<td>KGGLIKTKRRKRRK</td>
</tr>
</tbody>
</table>

| African Elephant   | SKFLIKTKRRKRRK | SKFLIKTKRRKRRK |
| Giant Panda        | KGGLIKTKRRKRRK | KGGLIKTKRRKRRK |
| Cow                | KGGLIKTKRRKRRK | KGGLIKTKRRKRRK |
| Dayak              | KGGLIKTKRRKRRK | KGGLIKTKRRKRRK |
| Horse              | KGGLIKTKRRKRRK | KGGLIKTKRRKRRK |
| Alpaca             | KGGLIKTKRRKRRK | KGGLIKTKRRKRRK |
| Pig                | KGGLIKTKRRKRRK | KGGLIKTKRRKRRK |
| Dog                | KGGLIKTKRRKRRK | KGGLIKTKRRKRRK |

---

From www.bloodjournal.org by guest on June 10, 2017. For personal use only.
Figure 5

![Diagram showing the activation of prothrombin and thrombin during the initiation and propagation phases.](diagram.png)
Biology of tissue factor pathway inhibitor

Jeremy P. Wood, Paul E.R. Ellery, Susan A. Maroney and Alan E. Mast